Novel Oral Therapy For the Mucopolysaccharidoses

Icahn School Of Medicine At Mount Sinai, New York NY

Investigators

Linked publications & trials

Abstract

DESCRIPTION (provided by applicant): Enzyme replacement therapies (ERTs) are available for three of the MPS, but do not significantly improve the cartilage, bone or spinal disease. Thus, treatment of these abnormalities in MPS patients represents an important unmet medical need. Pentosan polysulfate (PPS) is an FDA-approved, oral medication that has potent anti-inflammatory and clinical effects in animal models of several diseases, including osteoarthritis and intervertebral disc degeneration. It is currently approved for use in patients with interstitial cystitis, and its safety has been demonstrated through clinical testing. In this proposal PPS will be administered to MPS VI rats of various ages, including pregnant mothers, and the age-related effects on cartilage, bone and spinal disease will be evaluated by motility assays, microCT analyses of bone density and structure, histology, immunohistochemistry, biochemistry, and by biomechanical analysis of the structure and composition of bone, cartilage and spinal tissues. Aim 1 will examine oral administration of PPS to MPS VI animals of various ages; aim 2 will evaluate dose-related effects of oral PPS treatment; aim 3 will compare oral PPS to subcutaneous and intramuscular treatment; and aim 4 will evaluate the benefits of combined ERT/PPS treatment over ERT or PPS alone. PPS could represent the first oral medication for MPS, and if these experiments are successful could have a very high and immediate impact on the treatment and management of patients with these disorders.